In-hospital Outcomes of Percutaneous Left Ventricular Assist Device Recipients in Cardiogenic Shock Hospitalizations with Chronic Kidney Disease: A Nationwide Analysis.

Background: There is a lack of data on the role of chronic kidney disease (CKD) in patients who received percutaneous left ventricular assist devices (pLVAD) as mechanical circulatory support (MCS) as an adjunct treatment for cardiogenic shock (CS) management.

Methods: Using National Inpatient Sample (2016-19), we extracted CS patients receiving pLVAD and divided them into CKD and non-CKD cohorts. Multivariate regression analysis was used for adjusted odds ratios for outcomes before and after entropy balancing (EB) and predictive margins for the probability of all-cause in-hospital mortality (ACM).

Impact of Sarcoidosis in Patients Undergoing Aortic Valve Replacement: Insight from Nationwide Readmission Database 2016-2019.

It is not well-known if valve replacement outcomes differ in patients with sarcoidosis, especially in aortic valve intervention where the pressure gradients are physiologically high. In this retrospective study, we included all patients who underwent surgical/transcatheter aortic valve replacement from the National Readmission Database (2016-2019) and then divided them into those with and without sarcoidosis. Logistic and cox proportional hazard regression models were used.

Preferences for HIV PrEP care among gay, bisexual, and other men who have sex with men: a large discrete choice experiment.

Objective: We aimed to identify preferences for PrEP care among diverse gay, bisexual, and other men who have sex with men (BLGBM) in the US with discrete choice experiment (DCE).

Design: We conducted two DCEs to elicit care delivery preferences for Starting and Continuing PrEP among 16-49 year-old HIV negative GBM not using PrEP from across the United States. DCEs assessed preferences for care options including location, formulation (pills, injectable), lab testing, and costs.

Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation.

Introduction: The 2022 Inflation Reduction Act is expected to result in lower drug prices for Medicare beneficiaries in the United States (US). The Centers for Medicare & Medicaid Services (CMS) released the most recent draft guidance for the medicare drug price negotiation (DPN) program in May 2024.

Areas Covered: In August 2023, the list of 10 drugs selected for the DPN were published and the first round of negotiations are now complete.

Gastric Antral Vascular Ectasia Syndrome With Aortic Stenosis: A Twist on Heyde Syndrome?

Heyde syndrome is a triad of aortic stenosis (AS), gastrointestinal (GI) bleeding from angiodysplasia, and acquired von Willebrand disease (vWD). It is hypothesized that stenotic aortic valves cleave von Willebrand factor (vWF) multimers, predisposing patients to bleeding from GI angiodysplasias. This hypothesis is supported by the observation that aortic valve replacement often leads to the resolution of GI bleeding.